Updates are available Correction dated 2024-07-03

Article History

Received: 4 April 2024

Accepted: 2 May 2024

First Online: 25 May 2024

Change Date: 3 July 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41591-024-03156-7

Competing interests

: G.M.C. has served on the Board of Directors of Satellite Healthcare, a nonprofit dialysis provider. His institution (Stanford University) has received a grant from the trial sponsor, CSL Behring. G.M.C. has served as Chair or Cochair of Trial Steering Committees with Akebia, AstraZeneca, CSL Behring, Sanifit and Vertex. He has served as an Advisor to Alexion, Applaud, Ardelyx, CalciMedica, Calico, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset, Renibus and Unicycive. He has served as Chair or Member of Data Safety Monitoring Boards for clinical trials sponsored by Bayer, Mineralys and ReCor. A.M.C., M.H., R.C., J.M. and P.T. are employees of and hold stock in CSL Behring. E.V. is an employee of CSL Limited. G.M.F. received research grants from NIH, Bayer, BMS, Novartis, Daxor, Merck, Cytokinetics and CSL Behring. He has acted as a consultant to Novartis, BMS, Cytokinetics, Innolife, Boehringer Ingelheim, Abbott, Sanofi, Regeneron, Myovant, Sequana, Windtree Therapeutics and Whiteswell, and has served on clinical endpoint committees/data safety monitoring boards for Merck, Medtronic, EBR Systems, Rocket Pharma, V-Wave and LivaNova. B.F. has served in from CSL Behring. D.M.C. reports consultancy with Eli Lilly/Boehringer Ingelheim, AstraZeneca, Allena Pharmaceuticals (DSMB), Gilead, Novo Nordisk, GSK, Medtronic, Merck, CSL Behring, Zogenix, Renalytix and LG Chemical. He has received research funding from Medtronic, Gilead; Novo Nordisk; Amgen, Boehringer Ingelheim/Eli Lilly; and has held patents or royalties with UpToDate.com for authorship/editorials on reviews. C.M.G. receives research and consulting support from CSL Behring. S.G.G. received research grant support (for example, steering committee or data and safety monitoring committee) and/or speaker/consulting honoraria (for example, advisory boards) from CSL Behring, Alnylam, Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CYTE Ltd., Daiichi Sankyo/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, Idorsia, JAMP Pharma, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Regeneron, Roche, Sanofi, Servier, Tolmar Pharmaceuticals and Valeo Pharma and salary support/honoraria from the Canadian Heart Failure Society, Canadian Heart Research Center and MD Primer, Canadian VIGOUR Center, Cleveland Clinic Coordinating Center for Clinical Research, Duke Clinical Research Institute, Jewish General Hospital\CIUSSS Center-Ouest-de-l’Ile-de-Montreal, New York University Clinical Coordinating Center, PERFUSE Research Institute, Peter Munk Cardiac Center Clinical Trials and Translation Unit, Ted Rogers Heart Center and TIMI Study Group (Brigham Health). M.J. has received support from CSL Behring. A.L. has received support from CSL Behring. R.M. has received institutional research payments from Abbott, Abiomed, Affluent Medical, Alleviant Medical, Amgen, AM Pharma, Arena, AstraZeneca, AtriCure, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, CERC, Chiesi, Cleerly Health, Concept Medical, Cytosorbents, Daiichi Sankyo, Duke, Element Science, Essential Medical, Faraday, Idorsia Pharmaceuticals, Janssen, MedAlliance, Mediasphere, Medtelligence, Medtronic, MJH Healthcare, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi Cardia, PLx Pharma, Population Health Research Institute, Protembis, RecCor Medical, RenalPro, RM Global, Sanofi, Shockwave and Vivasure, Zoll. She received personal fees from Affluent Medical, Boehringer Ingelheim, Cardiovascular Research Foundation (CRF), Cordis, Daiichi Sankyo Brasil, E.R. Squibb Sons, Esperion Science/Innovative Biopharma, Europa Group/Boston Scientific, Gaffney Events, Educational Trust, Henry Ford Health Cardiology, Ionis Pharmaceuticals, Lilly and Company, MedCon International, Novartis, Novo Nordisk, PeerView Institute for Medical Education, TERUMO Europe N.V., Vectura, VoxMedia, WebMD, IQVIA, Radcliffe and TARSUS Cardiology. She received honoraria from the American Medical Association for her role as Associate Editor of <i>JAMA Cardiology</i>, ACC (BOT Member, SC Member CTR Program), and holds less than 1% equity in Elixir Medical, Stel. P.S. has received research support from AstraZeneca and Bayer. He has been a member of SAB for Baxter, FMC, Boehinger Mannheim, CSL, Alexion, GSK, lnvizius. D.C.W. has received honoraria/consultancy fees and/or speakers fees from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Eledon, Galderma, GSK, Gilead, Merck, Pharmacosmos, ProKidney, Tricida and Vifor. P.M.R. received institutional research grant support from Kowa, Novartis, Amarin, Pfizer, Esperion, Novo Nordisk and the NHLBI; during the past 5 years he has served as a consultant to Novartis, Flame, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Civi Biopharm, GSK, SOCAR, Novo Nordisk, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer Ingelheim and RTI; Zomagen, Cytokinetics, Horizon Therapeutics and Cardio Therapeutics. He has minority shareholder equity positions in Uppton, Bitterroot Bio and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR and the Baim Institute (Boston, MA). K.W.M. has received institutional and consulting funding from CSLB. M.W. has received research support from CSL through his institution, the Duke Clinical Research Institute, for the current study.